Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2014-03-31 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 92% confidence The document is a press release dated March 31, 2014, announcing a collaboration agreement between BioAlliance Pharma and Penn Pharma regarding the industrial development and manufacturing of the drug Validive®. This announcement details a business development/partnership, which is not explicitly covered by the core financial filing types (10-K, IR, ER, etc.). It is a specific corporate action announcement. Since it is not a Director's Dealing (DIRS), Major Shareholding (MRQ), Dividend (DIV), Capital Change (CAP), or Merger/Takeover (TAR), the most appropriate general category for significant corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), as it is a general regulatory announcement of a material event. However, given the content focuses on a specific business development (collaboration/partnership), and none of the provided codes perfectly match 'Business Development Announcement', RNS serves as the best fit among the available options for a non-standard, material corporate update.
2014-03-31 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated March 31, 2014, announcing a collaboration between BioAlliance Pharma and Penn Pharma for the industrial development and production of the drug Validive®. It details a business agreement, mentions ongoing clinical phases (Phase II/III), and includes forward-looking statements and boilerplate information about both companies. This type of announcement, detailing a strategic partnership or significant business development that is not a standard periodic financial report (like 10-K or IR), typically falls under general corporate news or regulatory filings. Since it is a specific announcement about a business transaction (collaboration/contract) rather than a change in management (MANG), financing (CAP), or a legal matter (LTR), it is best classified as a general Regulatory Filing (RNS) or potentially a general announcement if a more specific category doesn't fit. Given the options, RNS serves as the best catch-all for significant, non-standard corporate news releases that are not explicitly defined elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a presentation (IP).
2014-03-31 French
Communiqués en période d’offre / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a short press release dated March 28, 2014, announcing that BioAlliance Pharma will participate in the 'SmallCap Event' on April 7th and 8th, 2014, where management will meet institutional investors. It provides company background, product pipeline updates, and standard forward-looking statements. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed investor presentation (IP). It is an announcement about management engaging with investors regarding company news and strategy. Since it is an announcement about management meeting investors to present strategy and news, it aligns best with general investor relations communication, but given the specific options, it is a communication aimed at investors about upcoming engagement, which is often covered under Investor Presentation (IP) if it were the presentation itself, or a general Regulatory Filing (RNS) if it were a mandatory disclosure. However, the content focuses on management meeting investors to present strategy and outlook, which is a common activity detailed in Investor Presentations (IP) or general corporate updates. Given the context of presenting 'actualité, la stratégie de croissance et les perspectives' (news, growth strategy, and outlook) to investors, 'Investor Presentation' (IP) is the closest fit for the *topic* being discussed, even though this specific document is just the announcement of the meetings. Since it is a brief announcement about management meeting investors to discuss strategy, and not a formal report, it could also be RNS. However, the core subject matter is the presentation of strategy to investors. I will classify it as an Investor Presentation (IP) as it describes the content that will be presented, or RNS as a general announcement. Given the focus on management meeting investors to present strategy, IP is slightly more descriptive of the underlying activity than the general RNS fallback. However, applying the 'MENU VS MEAL' rule, this is an announcement, not the presentation itself. Therefore, RNS (Regulatory Filings - general announcement) is the safest classification for a brief announcement about an upcoming investor event.
2014-03-28 French
Communications during bidding periods / Other releases
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that BioAlliance Pharma management will participate in the 'Smallcap Event' to meet with institutional investors. This type of announcement, detailing management's schedule for meeting investors, is typically classified as Investor Presentation (IP) material or an announcement related to investor relations activities. Since it is an announcement about management meeting investors to present the company, it aligns closely with the purpose of an Investor Presentation (IP) or a general communication aimed at investors. It is not a formal regulatory filing like 10-K, an earnings release (ER), or a dividend notice (DIV). Given the context of management meeting investors to present the company, 'Investor Presentation' (IP) is the most fitting category, although it could also be considered a general regulatory filing (RNS) if IP was not available. However, IP covers presentations and strategy discussions for investors.
2014-03-28 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 95% confidence The document is a press release dated March 19, 2014, announcing two major business developments for BioAlliance Pharma: 1) Signing a licensing agreement with Innocutis for Sitavig® in North America, including financial terms and expected launch timelines. 2) Receiving favorable opinions from French and German Health Authorities for the Marketing Authorization of Sitavig® in Europe. This content details strategic business progress, licensing deals, and regulatory milestones, which is characteristic of a general corporate announcement or news release. It is not a formal regulatory filing like a 10-K, a specific financial report like an IR or ER, or a proxy statement. Given the nature of announcing strategic business updates, licensing deals, and regulatory progress, the most fitting category is a general Regulatory Filing (RNS) as a broad announcement, although it strongly resembles an Investor Presentation (IP) or Management Discussion (MDA) in content depth. However, since it is a press release format announcing multiple strategic events rather than a dedicated presentation deck or a detailed management analysis of financial results, RNS serves as the best fit among the provided options for a significant, non-standard corporate update, or potentially a general Investor Relations communication. Given the focus on business strategy and partnership, and lacking a specific 'Press Release' code, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for this type of material.
2014-03-19 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Capital/Financing Update Classification · 95% confidence The document is a press release dated March 19, 2014, announcing two major business developments for BioAlliance Pharma: 1) Signing a licensing agreement with Innocutis for Sitavig® in North America, including financial terms and expected launch timelines. 2) Receiving favorable opinions from French and German Health Authorities for the Marketing Authorization of Sitavig® in Europe. This content details strategic business progress, licensing deals, and regulatory milestones, which is characteristic of a general corporate announcement or news release. It is not a formal regulatory filing like a 10-K, a specific financial report like an IR or ER, or a proxy statement. Given the nature of announcing strategic business updates, licensing deals, and regulatory progress, the most fitting category is a general Regulatory Filing (RNS) as a broad announcement, although it strongly resembles an Investor Presentation (IP) or Management Discussion (MDA) in content depth. However, since it is a press release format announcing multiple strategic events rather than a dedicated presentation deck or a detailed management analysis of financial results, RNS serves as the best fit among the provided options for a significant, non-standard corporate update, or potentially a general Investor Relations communication. Given the focus on business strategy and partnership, and lacking a specific 'Press Release' code, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for this type of material.
2014-03-19 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.